Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Table 2 Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib

Clinical outcomes	With adverse events (n = 150)	Without adverse events (n = 119)	Unadjusted analysis		Multi-adjusted analysis^a
Clinical outcomes	With adverse events (n = 150)	Without adverse events (n = 119)	HR/OR^b (95% CI)	P value^c	HR/OR (95% CI)	P value^d
Median overall survival (IQR), days	169 (96–255)	103 (58–201)	0.67 (0.51,0.88)	0.0039	0.64 (0.48,0.84)	0.001
Median progression-free survival (IQR), days	86.5 (57–150)	62 (41–121)	0.75 (0.58,0.98)	0.0309	0.69 (0.53,0.91)	0.007
Disease control rate, n (%)	82 (54.67)	39 (32.77)	2.47 (1.46,4.21)	< 0.001	2.67 (1.59,4.47)	< 0.001
Objective response rate, n (%)	11 (7.33)	6 (5.04)	1.49 (0.49.5.06)	0.443	1.42 (0.50,4.01)	0.505

Adverse events are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment
HR hazard ratio, OR odds ratio, IQR interquartile range
^aAdjusted for sex, every 10-year increase in age, number of metastatic sites and ECOG PS
^bHR for overall survival and progression survival; OR for disease control rate and objective response rate
^cP values calculated from log-rank test for overall survival and progression survival, and chi-square test for disease control rate and objective response rate
^dP values calculated from Cox regression for overall survival and progression survival, and logistic regression for disease control rate and objective response rate

ISSN: 1756-8722